-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FlDem3ouZ2EIZWwU6p3FHBmTrds20vl1bdu81txPXU9p32F4X8uADjXsFQyzhZDv 5d9bH3SKrSTlRdLIsKKO1w== 0001181431-05-032153.txt : 20050611 0001181431-05-032153.hdr.sgml : 20050611 20050601165347 ACCESSION NUMBER: 0001181431-05-032153 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050527 ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20050601 DATE AS OF CHANGE: 20050601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIROPHARMA INC CENTRAL INDEX KEY: 0000946840 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232789550 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21699 FILM NUMBER: 05871310 BUSINESS ADDRESS: STREET 1: 397 EAGLEVIEW BLVD CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6104587300 MAIL ADDRESS: STREET 1: 397 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 8-K 1 rrd81175.htm 05.06.01 FORM 8K Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C., 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date Of Report (Date Of Earliest Event Reported):  05/27/2005
 
VIROPHARMA INCORPORATED
(Exact Name of Registrant as Specified in its Charter)
 
Commission File Number:  0-021699
 
DELAWARE
  
23-2789550
(State or Other Jurisdiction of
  
(I.R.S. Employer
Incorporation or Organization)
  
Identification No.)
 
397 Eagleview Boulevard, Exton, PA 19341
(Address of Principal Executive Offices, Including Zip Code)
 
610-458-7300
(Registrant’s Telephone Number, Including Area Code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
 

Items to be Included in this Report

 
Item 3.02.    Unregistered Sales of Equity Securities
 
Between May 27, 2005 and June 1, 2005, ViroPharma Incorporated received notices from holders of its 6% Convertible Senior Secured Notes due 2009 (the "Senior Convertible Notes") electing to voluntarily convert $4,250,000 principal amount of the Senior Convertible Notes into 1,700,000 shares of common stock at the conversion rate of one share of common stock for each $2.50 in principal amount of the Senior Convertible Notes. Following the conversions described above, approximately $61.23 million principal amount of the Senior Convertible Notes remained outstanding. The common stock was issued in reliance upon the exemption from the registration requirement of the Securities Act of 1933, as amended (the "Securities Act"), afforded by Section 3(a)(9) thereof.
 

 

Signature(s)
 
Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.
 
      
 
VIROPHARMA INCORPORATED
 
 
Date: June 01, 2005.
     
By:
 
/s/    Thomas F. Doyle
               
Thomas F. Doyle
               
Vice President, General Counsel and Secretary
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----